Skip to content
Peptigraph home

TRIUMPH-4: Retatrutide Phase 3 trial (NCT05931367)

A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
445
actual
Start
1 Aug 2023 (actual)
Primary completion
14 Nov 2025 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT05931367 study arms
ArmTypeInterventionsDescription
Retatrutide Dose 1ExperimentalDrug: RetatrutideParticipants will receive retatrutide subcutaneously (SC).
Retatrutide Dose 2ExperimentalDrug: RetatrutideParticipants will receive retatrutide SC.
PlaceboPlacebo comparatorDrug: PlaceboParticipants will receive placebo.
Endpoints

Primary endpoint

NCT05931367 primary outcomes
MeasureTime frame
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale ScoreBaseline, Week 68
Percent Change from Baseline in Body WeightBaseline, Week 68
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05931367 secondary outcomes
MeasureTime frame
Change from Baseline in the WOMAC Physical Function Subscale ScoreBaseline, Week 68
Change from Baseline in Waist CircumferenceBaseline, Week 68
Percent Change from Baseline in Total CholesterolBaseline, Week 68
Percent Change from Baseline in TriglyceridesBaseline, Week 68
Change from Baseline in Body Mass Index (BMI)Baseline, Week 68
Change from Baseline in Systolic Blood Pressure (SBP)Baseline, Week 68
Change from Baseline in Diastolic Blood Pressure (DBP)Baseline, Week 68
Percent Change from Baseline in Fasting InsulinBaseline, Week 68
Change from Baseline in Short Form 36-Version 2 (SF-36v2) Acute Form Physical Functioning Domain ScoreBaseline, Week 68
Change from Baseline in Average Pain Intensity Numeric Rating Score (API-NRS) ScoreBaseline, Week 68
Change from Baseline in Worst Pain Intensity Numeric Rating Score (WPI-NRS) ScoreBaseline, Week 68
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled TrialClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.